Efficiency of Interleukin-1 Blockade in Refractory Delayed-Pressure Urticaria
Authors: Cedric Lenormand, Dan Lipsker
Journal: Annals of Internal Medicine (2012)

Letters16 October 2012Efficiency of Interleukin-1 Blockade in Refractory Delayed-Pressure UrticariaCedric Lenormand, MD, PhD and Dan Lipsker, MD, PhDCedric Lenormand, MD, PhDFrom Clinique Dermatologique, Hopitaux Universitaires de Strasbourg, 67098 Strasbourg, France.Search for more papers by this author and Dan Lipsker, MD, PhDFrom Clinique Dermatologique, Hopitaux Universitaires de Strasbourg, 67098 Strasbourg, France.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-157-8-201210160-00023 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: Delayed-pressure urticaria is a rare form of physical urticaria that can be a highly incapacitating and treatment-refractory chronic condition (1). H1-antihistamines are ineffective, even at high doses, and various treatment options, including corticosteroids, nonsteroidal anti-inflammatory drugs, montelukast, colchicine, dapsone, intravenous immunoglobulin, and omalizumab, have been proposed with mitigated success. We report 2 cases of severe refractory delayed-pressure urticaria that had responded spectacularly to the interleukin-1–receptor antagonist anakinra.Case Report: The first patient, a 40-year-old man, presented with recurrent episodes of acute pain and swelling of the thighs, calves, and arms 5 to 10 hours after physical activity, often accompanied ...References1. Kobza-Black A. Delayed pressure urticaria. J Investig Dermatol Symp Proc. 2001;6:148-9. [PMID: 11764304] CrossrefMedlineGoogle Scholar2. Morioke S, Takahagi S, Iwamoto K, Shindo H, Mihara S, Kameyoshi Y, et al. Pressure challenge test and histopathological inspections for 17 Japanese cases with clinically diagnosed delayed pressure urticaria. Arch Dermatol Res. 2010;302:613-7. [PMID: 20480170] CrossrefMedlineGoogle Scholar3. Grundmann SA, Kiefer S, Luger TA, Brehier R. Delayed pressure urticaria—dapsone heading for first-line therapy? J Dtsch Dermatol Ges. 2011;9:908-12. [PMID: 21771275] MedlineGoogle Scholar4. Kieffer C, Cribier B, Lipsker D. Neutrophiic urticarial dermatosis: a variant of neutrophilic urticaria strongly associated with systemic disease. Report of 9 new cases and review of the literature. Medicine (Baltimore). 2009;88:23-31. [PMID: 19352297] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Clinique Dermatologique, Hopitaux Universitaires de Strasbourg, 67098 Strasbourg, France.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byOff-Label studies on anakinra in dermatology: a reviewCurrent and emerging pharmacotherapy for chronic spontaneous Urticaria: a focus on non-biological therapeuticsCanakinumab Lacks Efficacy in Treating Adult Patients with Moderate to Severe Chronic Spontaneous Urticaria in a Phase II Randomized Double-Blind Placebo-Controlled Single-Center StudyOff-label use of anti-IL-1 drugs in rheumatic diseasesCurrent and Potential Biologic Drugs for the Treatment of Chronic UrticariaBiologics for chronic inflammatory skin diseases: an update for the clinicianA Comprehensive Approach to Urticaria: From Clinical Presentation to Modern Biological Treatments Through PathogenesisNew treatments for chronic urticariaPresent and future in the treatment of chronic spontaneous urticariaEmerging Therapies in Chronic Spontaneous UrticariaNew biologics in the treatment of urticariaRole of Biologics and Future Perspectives in the Treatment of UrticariaLooking forward to new targeted treatments for chronic spontaneous urticariaThe Expanding Field of Biologics in the Management of Chronic UrticariaHistaminergic AngioedemaDelayed effort-induced swelling with myofasciitis and systemic manifestationsA Review and Proposed Approach to the Neutrophilic Dermatoses of ChildhoodUpdate and insights into treatment options for chronic spontaneous urticariaAnakinraAlternative Agents in Refractory Chronic Urticaria: Evidence and Considerations on Their Selection and UseInterleukin 1- β , Interleukin-1 Receptor Antagonist, and Interleukin 18 in Children with Acute Spontaneous Urticaria 16 October 2012Volume 157, Issue 8Page: 599-600KeywordsAbdominal painColchicineDrugsExerciseInflammationTemperatureType 2 diabetesUrticariaWeight gain ePublished: 16 October 2012 Issue Published: 16 October 2012 Copyright & PermissionsCopyright © 2012 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...